Legacy Medical Consultants Introduces Reeva FT™, a Full-Thickness Allograft for Enhanced Wound Treatment and Protection

Saturday, April 20, 2024

Legacy Medical Consultants (LMC) is excited to unveil its latest product offering, Reeva FT™, following the recent approval of the Q code.

This innovative solution is a terminally sterilized, full-thickness, dual-layered amnion/chorion allograft designed specifically for providing coverage and protection during advanced wound treatment.

Legacy Medical Consultants, highlights the importance of advanced allograft products in addressing the needs of the wound care space, emphasizing the company's commitment to innovation and advancement in medical technology.

About Reeva FT

Reeva FT represents a significant advancement in wound care technology. It is a lyophilized human placental-based allograft composed of amnion and chorion membranes, retaining the intermediate layer. This unique formulation offers a protective covering for acute and chronic wounds while also introducing a naturally derived extracellular matrix that serves as a supportive scaffold for native tissue during treatment. Reeva FT is capable of hydrostatically adhering to wounds and maintains a shelf life of five years when stored at ambient temperature.

Reeva FT is available in various sizes to accommodate different wound dimensions, including 2x2 cm, 2x3 cm, 4x4 cm, 4x6 cm, 4x8 cm, and 10x15 cm has been confirmed by the FDA Tissue Reference Group to meet the criteria for regulation under Section 361 of the Public Health Service (PHS) Act, as defined in 21 CFR Part 1271.
The recent announcement by CMS regarding HCPCS Level II code Q4314 further underscores the significance of Reeva FT in the medical community.


Harvard Medical School - Leadership in Medicine Southeast Asia47th IHF World Hospital CongressHealthcare Innovation & Transformation SummitHealthcare CNO SummitHealthcare CMO SummitThe Healthcare Patient Experience & Engagement Summit 2024